On June 11, 2024, Zai Lab Limited (the ?Company?) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024, after which he will serve as a senior advisor for the Company. On June 11, 2024, the Company also announced that Dr. Rafael Amado, President, Head of Global Oncology Research and Development, will be expanding his role to President, Head of Global Research and Development, effective upon Dr. Reinhart?s retirement on June 30, 2024. As Head of Global R&D, Dr. Amado will continue to advance Zai Lab?s existing and future pipelines across all therapy areas.

He has held senior positions and advisory roles in pharmaceutical and biotechnology companies where he was responsible for the discovery and development of a variety of products, across modalities and therapeutic areas.